Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
about
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activationProteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspaseHuman inhibitor of apoptosis proteins: why XIAP is the black sheep of the familyFeatures of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinityDiscovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)The structure of XIAP BIR2: understanding the selectivity of the BIR domainsEngineering archeal surrogate systems for the development of protein-protein interaction inhibitors against human RAD51Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells.p42MAPK-mediated phosphorylation of xEIAP/XLX in Xenopus cytostatic factor-arrested egg extracts.Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3.Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma.Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomasInhibitor of apoptosis (IAP)-like protein lacks a baculovirus IAP repeat (BIR) domain and attenuates cell death in plant and animal systemsSynthetic mimetics of protein secondary structure domainsClassification of scaffold-hopping approachesRole of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migrationInhibition of caspase-9 by stabilized peptides targeting the dimerization interface.Inhibitor of apoptosis proteins and apoptosis.Expression and clinical significance of livin protein in hepatocellular carcinoma.Inhibitor of apoptosis proteins in hematological malignancies.The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular StressSmall-molecule pan-IAP antagonists: a patent review.Targeting inhibitor of apoptosis proteins for therapeutic intervention.Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists.Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy.Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.Characterization of ML-IAP protein stability and physiological role in vivo.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Saikosaponin-d Enhances the Anticancer Potency of TNF-α via Overcoming Its Undesirable Response of Activating NF-Kappa B Signalling in Cancer Cells.Internal motions prime cIAP1 for rapid activation.Development of Peptidomimetics Targeting IAPsIAP proteins: sticking it to Smac.The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
P2860
Q24607621-5CFD969A-5D80-485C-AD01-C8F87EB570F3Q24656141-1CC5B124-4426-49AF-952C-4776A0E3FA10Q24670396-577F54D0-2D3B-4345-A002-7DB73B43B19EQ26996645-50CAD5A6-E7DC-4AC1-82A9-D79310702F27Q27678027-A09BB361-CC04-4CEF-8C58-0907B63F2FB9Q27679855-2508AB89-0CE7-41C3-9C54-7D76A6DE867EQ27728438-4BF3DA72-21CB-4DD8-915D-4D350261A43FQ27851964-50822AA3-9766-4E45-8A3E-D9AAF231C85BQ33281715-699DC545-EC7C-4240-9F2A-34C2FA8E0860Q33933676-20BD09AB-F814-4AF0-BACD-074818DD6B7EQ34334545-563A5A74-DDAC-4170-AC26-0179C3D66E5DQ34429203-B07D6D7B-B22C-4F41-B085-986005C4623DQ35119355-F1382290-DD41-46C2-8925-C60C36E6A9E2Q35588764-6C499509-A7CE-4768-84E9-F5BAFC710D51Q35604905-06347CAC-E463-4E68-8F1E-C4AD265A9768Q35688001-B371409E-28C4-4C9C-8B14-30EB5BBF901FQ35893996-DD9767E7-1EE0-440F-8B97-F989C15ABCF1Q36217262-ABCC3312-BC78-4D77-9406-E3E863EF520FQ36529717-B3D9A2E7-1D86-45C7-9DC7-BED8D7720168Q37134050-3E34818D-C6E4-421C-B731-2135261F7072Q37260289-D5287335-634B-4008-A06D-BEC2ED6E846BQ37336610-9AA12406-40ED-48B0-90F1-499070ADD46BQ37512362-B7239221-542F-4588-B3C4-1CAABDE26111Q37680967-F8432A23-72C9-43BD-996D-94C9E3C72786Q37855868-3D270E8A-F276-43C7-99B0-6A04B86E07AAQ37875078-4ADB1942-2FC8-4993-8523-D7BA049C1B54Q37974461-103AFD6F-8E82-4EAB-AD38-8B099A36D7A7Q38087851-0E56E94F-16B3-49FE-B6F7-B11F88C782A2Q38183402-D4DDD16C-5B2C-4302-A374-BE595AA74FD7Q38184343-AC292A1C-EFF0-4A31-88FC-0E02B698AFE6Q39304168-30AA8D74-78A8-4923-9B9B-8AB5A6D777F0Q39312652-1CDF2521-FE47-4C74-931E-DB4296140B60Q39375981-F989B994-49D3-4DE4-B469-BAA3A382C84BQ41792395-2A27AF6E-5D4D-475E-924C-EDA4B706EF18Q41911916-10764C6A-A8A4-416D-A75B-80AF927AA685Q42813655-CC37A89C-99CB-4D3F-9565-4522D27221E2Q46200610-18849FE2-D602-4AD9-9153-D168978A0561Q51746852-FCB26E6C-C85C-48CB-8761-6B174A042697
P2860
Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Engineering ML-IAP to produce ...... -apoptotic activity of ML-IAP.
@en
type
label
Engineering ML-IAP to produce ...... -apoptotic activity of ML-IAP.
@en
prefLabel
Engineering ML-IAP to produce ...... -apoptotic activity of ML-IAP.
@en
P2093
P2860
P356
P1433
P1476
Engineering ML-IAP to produce ...... -apoptotic activity of ML-IAP.
@en
P2093
Brendan P Eckelman
Domagoj Vucic
Guy S Salvesen
Heidi J A Wallweber
Hwain Shin
Kurt Deshayes
Linda O Elliott
Matthew C Franklin
Saloumeh Kadkhodayan
P2860
P356
10.1042/BJ20041108
P407
P577
2005-01-01T00:00:00Z